RADIOTELEMETRIC BP MONITORING, ANTIHYPERTENSIVES AND GLOMERULOPROTECTION IN REMNANT KIDNEY MODEL
RADIOTELEMETRIC BP MONITORING, ANTIHYPERTENSIVES AND GLOMERULOPROTECTION IN REMNANT KIDNEY MODEL
复制标题
DOI：
10.1038/ki.1994.361
复制
发表时间：
1994-10-01
影响因子：
19.6
通讯作者：
BIDANI, AK
中科院分区：
文献类型：
--
作者：
GRIFFIN, KA;PICKEN, M;BIDANI, AK
抗高血压药物在残肾模型中发挥肾小球保护作用的机制仍存在争议。根据定期尾套血压测量，抗高血压药物不同的肾小球保护功效归因于其降低血压能力之外的机制。为了更精确地定义血压控制和肾小球保护之间的关系，在类似于 5/6 肾脏消融后，以 10 分钟的间隔对大鼠进行连续大约 65 天的收缩压监测。具有残余肾脏的大鼠在第一周后要么不接受任何治疗，要么在饮用水中接受三种抗高血压治疗方案中的一种：依那普利，三联治疗方案（利血平、肼屈嗪、氢氯噻嗪）；或高剂量三联疗法。尽管所有抗高血压治疗方案均显着降低血压，但观察到相当大的动物间差异。此外，未治疗和治疗的大鼠中均存在明显的血压不稳定性。个体动物 (N = 34) 的肾小球损伤与其最后八周内的总体平均收缩压 (r = 0.91) 以及收缩压读数 >150 mm Hg 的频率 (r = 0.89) 密切相关。这些数据并没有提供任何治疗方案的独立于其抗高血压作用的治疗优势的证据，但表明这些抗高血压治疗方案的肾小球保护功效与其抗高血压效率成正比。
The mechanisms by which antihypertensives exert a glomeruloprotective effect in the remnant kidney model remain controversial. Based on periodic tail-cuff BP measurements, the variable glomeruloprotective efficacy of antihypertensive agents has been ascribed to mechanisms other than or in addition to their ability to lower BP. To more precisely define the relationship between BP control and glomeruloprotection, systolic BP was continuously monitored radiotelemetrically at 10-minute intervals for similar to 65 days in rats after similar to 5/6 renal ablation. Rats with remnant kidneys received either no therapy or one of three antihypertensive regimens in their drinking water after the first week: enalapril, a triple therapy regimen (reserpine, hydralazine, hydrochlorothiazide); or a high dose triple therapy regimen. Although all antihypertensive regimens significantly lowered BP, considerable interanimal variability was observed. Additionally, marked lability of BP was present in both untreated and treated rats. Glomerular injury in individual animals (N = 34) was very strongly correlated with their overall averaged systolic BP during the final eight weeks (r = 0.91) and with the frequency of systolic BP readings >150 mm Hg (r = 0.89). These data do not provide evidence of a therapeutic advantage for any of the regimens independent of their antihypertensive effects but indicate that the glomeruloprotective efficacy of these antihypertensive regimens is directly proportional to their antihypertensive efficiency.